VistaGen Therapeutics, Inc is a biotechnology business based in the US. VistaGen Therapeutics shares (VTGN) are listed on the NASDAQ and all prices are listed in US Dollars. VistaGen Therapeutics employs 21 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in VistaGen Therapeutics
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – VTGN – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
VistaGen Therapeutics stock price (NASDAQ: VTGN)Use our graph to track the performance of VTGN stocks over time.
VistaGen Therapeutics shares at a glance
|Latest market close||$2.63|
|52-week range||$0.56 - $3.55|
|50-day moving average||$2.86|
|200-day moving average||$2.42|
|Wall St. target price||$6.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.83|
Buy VistaGen Therapeutics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy VistaGen Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
VistaGen Therapeutics price performance over time
|1 week (2021-07-17)||N/A|
|1 month (2021-06-28)||-7.39%|
|3 months (2021-04-28)||7.79%|
|6 months (2021-01-24)||N/A|
|1 year (2020-07-24)||N/A|
|2 years (2019-07-24)||N/A|
|3 years (2018-07-24)||N/A|
|5 years (2016-07-24)||N/A|
VistaGen Therapeutics financials
|Revenue TTM||$1.1 million|
|Gross profit TTM||$1.1 million|
|Return on assets TTM||-19.66%|
|Return on equity TTM||-36.78%|
|Market capitalisation||$556.9 million|
TTM: trailing 12 months
Shorting VistaGen Therapeutics shares
There are currently 12.3 million VistaGen Therapeutics shares held short by investors – that's known as VistaGen Therapeutics's "short interest". This figure is 88.5% up from 6.5 million last month.
There are a few different ways that this level of interest in shorting VistaGen Therapeutics shares can be evaluated.
VistaGen Therapeutics's "short interest ratio" (SIR)
VistaGen Therapeutics's "short interest ratio" (SIR) is the quantity of VistaGen Therapeutics shares currently shorted divided by the average quantity of VistaGen Therapeutics shares traded daily (recently around 3.2 million). VistaGen Therapeutics's SIR currently stands at 3.83. In other words for every 100,000 VistaGen Therapeutics shares traded daily on the market, roughly 3830 shares are currently held short.
However VistaGen Therapeutics's short interest can also be evaluated against the total number of VistaGen Therapeutics shares, or, against the total number of tradable VistaGen Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case VistaGen Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 VistaGen Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.081% of the tradable shares (for every 100,000 tradable VistaGen Therapeutics shares, roughly 81 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against VistaGen Therapeutics.
Find out more about how you can short VistaGen Therapeutics stock.
VistaGen Therapeutics share dividends
We're not expecting VistaGen Therapeutics to pay a dividend over the next 12 months.
Have VistaGen Therapeutics's shares ever split?
VistaGen Therapeutics's shares were split on a 1:20 basis on 13 August 2014. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your VistaGen Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for VistaGen Therapeutics shares which in turn could have impacted VistaGen Therapeutics's share price.
VistaGen Therapeutics share price volatility
Over the last 12 months, VistaGen Therapeutics's shares have ranged in value from as little as $0.5551 up to $3.55. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while VistaGen Therapeutics's is 0.8923. This would suggest that VistaGen Therapeutics's shares are less volatile than average (for this exchange).
VistaGen Therapeutics overview
VistaGen Therapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd. ; license and option agreements with Pherin Pharmaceuticals, Inc.
Stocks similar to VistaGen Therapeutics
VistaGen Therapeutics in the news
VistaGen Therapeutics Announces Appointment of Maggie FitzPatrick to its Board of Directors
VistaGen Therapeutics Announces Appointment of Maggie FitzPatrick to its Board of Directors
VistaGen Therapeutics appoints Maggie FitzPatrick to board of directors
Frequently asked questionsWhat percentage of VistaGen Therapeutics is owned by insiders or institutions?
Currently 0.227% of VistaGen Therapeutics shares are held by insiders and 60.734% by institutions. How many people work for VistaGen Therapeutics?
Latest data suggests 21 work at VistaGen Therapeutics. When does the fiscal year end for VistaGen Therapeutics?
VistaGen Therapeutics's fiscal year ends in March. Where is VistaGen Therapeutics based?
VistaGen Therapeutics's address is: 343 Allerton Avenue, South San Francisco, CA, United States, 94080 What is VistaGen Therapeutics's ISIN number?
VistaGen Therapeutics's international securities identification number is: US92840H2022 What is VistaGen Therapeutics's CUSIP number?
VistaGen Therapeutics's Committee on Uniform Securities Identification Procedures number is: 92840H103
More guides on Finder
How to buy Clover Finance (CLV) in the US
This guide will show you step-by-step instructions on how to buy the Clover Finance (CLV) token as well as a list of exchanges you can trade it on.
How to buy AT-and-T (T) stock
Steps to owning and managing T, with 24-hour and historical pricing before you buy.
How to buy HNC Coin (HNC) in the US
This guide will show you step-by-step instructions on how to buy the Hellenic Coin (HNC) token as well as a list of exchanges you can trade it on.
How to buy Maro (MARO) in the US
This guide will show you step-by-step instructions on how to buy the Maro (MARO) token as well as a list of exchanges you can trade it on.
How to buy Ethernity Chain (ERN) in the US
This guide will show you step-by-step instructions on how to buy the Ethernity Chain (ERN) token as well as a list of exchanges you can trade it on.
How to buy Shopping.io (SPI) in the US
This guide will show you step-by-step instructions on how to buy the Shopping.io (SPI) token as well as a list of exchanges you can trade it on.
How to buy LUKSO Token (LYXE) in the US
This guide will show you step-by-step instructions on how to buy the LUKSO Token (LYXE) token as well as a list of exchanges you can trade it on.
How to buy KardiaChain (KAI) in the US
This guide will show you step-by-step instructions on how to buy the KardiaChain (KAI) token as well as a list of exchanges you can trade it on.
How to buy Neutrino USD (USDN) in the US
This guide will show you step-by-step instructions on how to buy the Neutrino USD (USDN) token as well as a list of exchanges you can trade it on.
How to buy Venus BTC (VBTC) in the US
This guide will show you step-by-step instructions on how to buy the Venus BTC (VBTC) token as well as a list of exchanges you can trade it on.
Ask an Expert